GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Avant Diagnostics Inc (GREY:AVDX) » Definitions » EBITDA Margin %

Avant Diagnostics (Avant Diagnostics) EBITDA Margin % : 0.00% (As of Dec. 2018)


View and export this data going back to 2009. Start your Free Trial

What is Avant Diagnostics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Avant Diagnostics's EBITDA for the three months ended in Dec. 2018 was $-0.44 Mil. Avant Diagnostics's Revenue for the three months ended in Dec. 2018 was $0.00 Mil. Therefore, Avant Diagnostics's EBITDA margin for the quarter that ended in Dec. 2018 was 0.00%.


Avant Diagnostics EBITDA Margin % Historical Data

The historical data trend for Avant Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avant Diagnostics EBITDA Margin % Chart

Avant Diagnostics Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Sep14 Sep15 Sep16 Sep17 Sep18
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -9,580.51 -3,298.05 -

Avant Diagnostics Quarterly Data
Jan14 Apr14 Jul14 Oct14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avant Diagnostics's EBITDA Margin %

For the Diagnostics & Research subindustry, Avant Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avant Diagnostics's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Avant Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Avant Diagnostics's EBITDA Margin % falls into.



Avant Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Avant Diagnostics's EBITDA Margin % for the fiscal year that ended in Sep. 2018 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2018 )/Revenue (A: Sep. 2018 )
=-1.898/0
= %

Avant Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2018 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2018 )/Revenue (Q: Dec. 2018 )
=-0.436/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avant Diagnostics  (GREY:AVDX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Avant Diagnostics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Avant Diagnostics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avant Diagnostics (Avant Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
1050 30th Street NW, Suite 107, Washington, DC, USA, 20007
Avant Diagnostics Inc is a medical diagnostic technology company. Business activity of the group is functioned through United States. It focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The company's premier product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer.

Avant Diagnostics (Avant Diagnostics) Headlines